Chinese expert consensus on diagnosis and treatment strategies for novel coronavirus infection in immunocompromised populations (2023 edition)

Ju, Chunrong1; Wang, Meiying2; Yuan, Jing3; Xu, Yonghao1; Xue, Wujun4,5; Lu, Hongzhou4,6; Li, Yimin4,7; Li, Shiyue4,8

2024-02-01

10.1111/1756-185X.14998

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES   影响因子和分区

1756-1841

1756-185X

Since the coronavirus disease 2019 (COVID-19) was identified in 2019, it has caused more than 664 million confirmed cases and more than 6.7 million deaths globally by January 20, 2023. So far, the novel coronavirus has undergone mutations from the original, Alpha, Delta, and Omicron strains. Omicron was first detected in South Africa in November 2021 and has since spread rapidly to more than 100 countries around the world, leading the World Health Organization (WHO) to classify it as a "variant of concern" for COVID-19. Due to its stronger infectivity, faster transmission, and higher reinfection rate, it is more likely to cause immune evasion and infection breakthrough in the vaccinated population. Omicron has replaced Delta strain as the main epidemic strain imported from overseas and in China. People with immunodeficiency are more susceptible to the novel coronavirus due to abnormal immune function, and viral infections tend to be more lasting and severe. In addition, due to the existence of underlying diseases, most people with immunodeficiency have been taking immunosuppressants and other related drugs for a long time, and there are different degrees of interaction between novel coronavirus treatment drugs and original drugs, which brings great challenges to the diagnosis and treatment of people with immunodeficiency after infection with novel coronavirus. According to the Novel Coronavirus Infection Diagnosis and Treatment Protocol (Trial 10th Edition) issued by the National Health Commission, which emphasizes "strengthening the protection of key groups," people with immune deficiency belong to the high-risk groups of severe or critical disease. Based on the evidence of evidence-based medicine and after many discussions by experts from multiple disciplines (Department of Respiratory and Critical Care, Department of Organ Transplantation, Department of Rheumatology, Department of Hematology, Department of Infection, Department of Critical Care Medicine, etc.), 13 recommendations are summarized to provide theoretical and practical reference for the diagnosis and treatment strategy of this special population.

COVID-19 immunodeficient population molecule drug pneumonia

SCI

英语

其他

Rheumatology

Rheumatology

WOS:001157366800001

WILEY

Web of Science

1.Guangzhou Med Univ, Guangzhou Inst Resp Hlth, Natl Ctr Resp Med, State Key Lab Resp Dis,Affiliated Hosp 1, Guangzhou, Peoples R China
2.Shenzhen Univ, Shenzhen Peoples Hosp 2, Res Ctr Natl Biochem Engn Technol, Affiliated Hosp 1, Shenzhen, Peoples R China
3.Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Natl Clin Res Ctr Infect Dis, Affiliated Hosp 2, Shenzhen, Peoples R China
4.China Med Educ Assoc, Expert Comm Infect Dis, Organ Transplantat Branch, Infect Dis Soc China,Chinese Med Assoc, Beijing, Peoples R China
5.Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Kidney Transplantat, Xian, Peoples R China
6.Shenzhen Third Peoples Hosp, Dept Infect Dis, Shenzhen, Peoples R China
7.Guangzhou Med Univ, Dept Crit Care Med, Affiliated Hosp 1, Guangzhou, Peoples R China
8.Guangzhou Med Univ, Dept Resp & Crit Care Med, Guangzhou, Peoples R China

Ju, Chunrong,Wang, Meiying,Yuan, Jing,et al. Chinese expert consensus on diagnosis and treatment strategies for novel coronavirus infection in immunocompromised populations (2023 edition)[J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES,2024,27(2).

Ju, Chunrong.,Wang, Meiying.,Yuan, Jing.,Xu, Yonghao.,Xue, Wujun.,...&Li, Shiyue.(2024).Chinese expert consensus on diagnosis and treatment strategies for novel coronavirus infection in immunocompromised populations (2023 edition).INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES,27(2).

Ju, Chunrong,et al."Chinese expert consensus on diagnosis and treatment strategies for novel coronavirus infection in immunocompromised populations (2023 edition)".INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES 27.2(2024).